questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Nucléoprotéines
Protéines chromosomiques nonhistones
Protéines HMG
Protéines HMGB
Protéine HMGB3
Protéine HMGB3 : Questions médicales fréquentes
Diagnostic
5
Protéines
Tests génétiques
Immunohistochimie
Dosage protéique
Biopsie
Expression génique
Marqueurs tumoraux
Prolifération cellulaire
Sang
Protéines plasmatiques
Symptômes
5
Maladies auto-immunes
Cancers
Survie cellulaire
Stress oxydatif
Tumeurs
Troubles immunitaires
Symptômes cliniques
Tests diagnostiques
Prévention
5
Prévention
Dépistage précoce
Facteurs de risque
Toxines
Alimentation
Antioxydants
Stress oxydatif
Expression génique
Vaccinations
Réponse immunitaire
Traitements
5
Thérapies ciblées
Inhibiteurs de protéines
Immunothérapie
Cibles thérapeutiques
Médicaments
Expression génique
Essais cliniques
Traitements expérimentaux
Efficacité thérapeutique
Stades du cancer
Complications
5
Complications
Cancers avancés
Maladies auto-immunes
Aggravation
Récidive tumorale
Niveaux de protéines
Réversibilité
Gestion des complications
Facteurs de risque
5
Facteurs de risque
Agents cancérigènes
Hérédité
Antécédents familiaux
Infections virales
Régulation
Exposition professionnelle
Produits chimiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéine HMGB3 : Questions médicales les plus fréquentes",
"headline": "Protéine HMGB3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéine HMGB3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-17",
"dateModified": "2026-04-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéine HMGB3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines HMGB",
"url": "https://questionsmedicales.fr/mesh/D024002",
"about": {
"@type": "MedicalCondition",
"name": "Protéines HMGB",
"code": {
"@type": "MedicalCode",
"code": "D024002",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.235.400.600"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéine HMGB3",
"alternateName": "HMGB3 Protein",
"code": {
"@type": "MedicalCode",
"code": "D025765",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yang Zhang",
"url": "https://questionsmedicales.fr/author/Yang%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Qingdao University Medical College Affiliated Yantai Yuhuangding Hospital, Yantai, China."
}
},
{
"@type": "Person",
"name": "Wei Guo",
"url": "https://questionsmedicales.fr/author/Wei%20Guo",
"affiliation": {
"@type": "Organization",
"name": "The Second Affiliated Hospital & Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China."
}
},
{
"@type": "Person",
"name": "Hui Li",
"url": "https://questionsmedicales.fr/author/Hui%20Li",
"affiliation": {
"@type": "Organization",
"name": "Zhejiang University, Hangzhou, Zhejiang, China."
}
},
{
"@type": "Person",
"name": "Hanlin Ma",
"url": "https://questionsmedicales.fr/author/Hanlin%20Ma",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, 250012, China."
}
},
{
"@type": "Person",
"name": "Gonghua Qi",
"url": "https://questionsmedicales.fr/author/Gonghua%20Qi",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, 250012, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "HMGB3 promotes the malignant phenotypes and stemness of epithelial ovarian cancer through the MAPK/ERK signaling pathway.",
"datePublished": "2023-06-16",
"url": "https://questionsmedicales.fr/article/37328851",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12964-023-01172-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Structure and Functions of HMGB3 Protein.",
"datePublished": "2024-07-12",
"url": "https://questionsmedicales.fr/article/39062899",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25147656"
}
},
{
"@type": "ScholarlyArticle",
"name": "Circ_LDLR promotes the progression of papillary thyroid carcinoma by regulating miR-1294/HMGB3 axis.",
"datePublished": "2023-08-11",
"url": "https://questionsmedicales.fr/article/37565296",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jbt.23498"
}
},
{
"@type": "ScholarlyArticle",
"name": "Exosomal HMGB3 released by glioma cells confers the activation of NLRP3 inflammasome and pyroptosis in tumor-associated macrophages.",
"datePublished": "2024-05-12",
"url": "https://questionsmedicales.fr/article/38761792",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.tice.2024.102406"
}
},
{
"@type": "ScholarlyArticle",
"name": "CircRUNX1 drives the malignant phenotypes of lung adenocarcinoma through mediating the miR-5195-3p/HMGB3 network.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37474742",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11748-023-01960-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Nucléoprotéines",
"item": "https://questionsmedicales.fr/mesh/D009698"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines chromosomiques nonhistones",
"item": "https://questionsmedicales.fr/mesh/D002868"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines HMG",
"item": "https://questionsmedicales.fr/mesh/D006609"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protéines HMGB",
"item": "https://questionsmedicales.fr/mesh/D024002"
},
{
"@type": "ListItem",
"position": 8,
"name": "Protéine HMGB3",
"item": "https://questionsmedicales.fr/mesh/D025765"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéine HMGB3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéine HMGB3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéine HMGB3",
"description": "Comment diagnostiquer une anomalie de HMGB3 ?\nQuels tests sont utilisés pour évaluer HMGB3 ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels marqueurs sont associés à HMGB3 ?\nPeut-on détecter HMGB3 dans le sang ?",
"url": "https://questionsmedicales.fr/mesh/D025765#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéine HMGB3",
"description": "Quels symptômes sont liés à une surproduction de HMGB3 ?\nHMGB3 est-il associé à des maladies spécifiques ?\nComment HMGB3 affecte-t-il la santé cellulaire ?\nY a-t-il des signes cliniques d'anomalies de HMGB3 ?\nLes symptômes de HMGB3 sont-ils visibles ?",
"url": "https://questionsmedicales.fr/mesh/D025765#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéine HMGB3",
"description": "Peut-on prévenir les anomalies de HMGB3 ?\nY a-t-il des facteurs de risque pour HMGB3 ?\nL'alimentation influence-t-elle HMGB3 ?\nLe stress a-t-il un impact sur HMGB3 ?\nDes vaccinations peuvent-elles influencer HMGB3 ?",
"url": "https://questionsmedicales.fr/mesh/D025765#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéine HMGB3",
"description": "Quels traitements ciblent HMGB3 ?\nHMGB3 peut-il être une cible pour l'immunothérapie ?\nComment les médicaments affectent-ils HMGB3 ?\nY a-t-il des essais cliniques sur HMGB3 ?\nLes traitements sont-ils efficaces contre HMGB3 ?",
"url": "https://questionsmedicales.fr/mesh/D025765#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéine HMGB3",
"description": "Quelles complications sont liées à HMGB3 ?\nHMGB3 peut-il aggraver des maladies existantes ?\nY a-t-il des risques de récidive liés à HMGB3 ?\nComment HMGB3 influence-t-il le pronostic ?\nLes complications de HMGB3 sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D025765#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéine HMGB3",
"description": "Quels sont les principaux facteurs de risque pour HMGB3 ?\nL'hérédité joue-t-elle un rôle dans HMGB3 ?\nLe mode de vie influence-t-il HMGB3 ?\nLes infections peuvent-elles affecter HMGB3 ?\nL'exposition professionnelle influence-t-elle HMGB3 ?",
"url": "https://questionsmedicales.fr/mesh/D025765#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie de HMGB3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de protéines peuvent être utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer HMGB3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'immunohistochimie et les dosages protéiques sont courants."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une biopsie peut être nécessaire pour évaluer l'expression de HMGB3."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés à HMGB3 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "HMGB3 est souvent associé à des marqueurs de prolifération cellulaire."
}
},
{
"@type": "Question",
"name": "Peut-on détecter HMGB3 dans le sang ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que HMGB3 peut être détecté dans des échantillons sanguins."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une surproduction de HMGB3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surproduction peut être liée à des symptômes de cancer ou d'inflammation."
}
},
{
"@type": "Question",
"name": "HMGB3 est-il associé à des maladies spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, HMGB3 est associé à des cancers et des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment HMGB3 affecte-t-il la santé cellulaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "HMGB3 joue un rôle dans la survie cellulaire et la réponse au stress."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques d'anomalies de HMGB3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cliniques peuvent inclure des tumeurs ou des troubles immunitaires."
}
},
{
"@type": "Question",
"name": "Les symptômes de HMGB3 sont-ils visibles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes ne sont pas toujours visibles et nécessitent des tests spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies de HMGB3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain et le dépistage précoce."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque pour HMGB3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme le tabagisme et l'exposition à des toxines augmentent les risques."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle HMGB3 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut aider à réguler HMGB3."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur HMGB3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut affecter l'expression de HMGB3."
}
},
{
"@type": "Question",
"name": "Des vaccinations peuvent-elles influencer HMGB3 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent moduler la réponse immunitaire liée à HMGB3."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent HMGB3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des inhibiteurs de protéines peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "HMGB3 peut-il être une cible pour l'immunothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, HMGB3 est étudié comme cible potentielle pour l'immunothérapie."
}
},
{
"@type": "Question",
"name": "Comment les médicaments affectent-ils HMGB3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent moduler l'expression de HMGB3 dans les cellules."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques sur HMGB3 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques évaluent les traitements ciblant HMGB3."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces contre HMGB3 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie selon le type de cancer et le stade de la maladie."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à HMGB3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des cancers avancés et des troubles immunitaires."
}
},
{
"@type": "Question",
"name": "HMGB3 peut-il aggraver des maladies existantes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surproduction de HMGB3 peut aggraver des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de récidive liés à HMGB3 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés de HMGB3 sont associés à un risque accru de récidive tumorale."
}
},
{
"@type": "Question",
"name": "Comment HMGB3 influence-t-il le pronostic ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de HMGB3 peuvent indiquer un pronostic défavorable dans certains cancers."
}
},
{
"@type": "Question",
"name": "Les complications de HMGB3 sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais pas toutes sont réversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour HMGB3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le tabagisme et l'exposition à des agents cancérigènes."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans HMGB3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque lié à HMGB3."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il HMGB3 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles affecter HMGB3 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales sont liées à une régulation anormale de HMGB3."
}
},
{
"@type": "Question",
"name": "L'exposition professionnelle influence-t-elle HMGB3 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques dans certains emplois peut augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 08/04/2026
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
Qingdao University Medical College Affiliated Yantai Yuhuangding Hospital, Yantai, China.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
The Second Affiliated Hospital & Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Zhejiang University, Hangzhou, Zhejiang, China.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Gynecologic Oncology Key Laboratory of Shandong Province, Qilu Hospital of Shandong University, Jinan, 250012, China.
School of Medicine, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Gynecologic Oncology Key Laboratory of Shandong Province, Qilu Hospital of Shandong University, Jinan, 250012, China.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, 250012, China.
Gynecologic Oncology Key Laboratory of Shandong Province, Qilu Hospital of Shandong University, Jinan, 250012, China.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, 250012, China. kongbeihua@sdu.edu.cn.
Gynecologic Oncology Key Laboratory of Shandong Province, Qilu Hospital of Shandong University, Jinan, 250012, China. kongbeihua@sdu.edu.cn.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Neurosurgery, Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Nanchang, 330006, Jiangxi Province, People's Republic of China.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Stomatology, The First Hospital of Qiqihar (The Affiliated Qiqihar Hospital of Southern Medical University), Qiqihar, Heilongjiang, 161000, People's Republic of China.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu 600036, India.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu 600036, India.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu 600036, India.
Publications dans "Protéine HMGB3" :
2 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu 600036, India. Electronic address: karuna@iitm.ac.in.
Publications dans "Protéine HMGB3" :
1 publication dans cette catégorie
Affiliations :
Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky Av. 4, 194064 St. Petersburg, Russia.
Publications dans "Protéine HMGB3" :
1 publication dans cette catégorie
Affiliations :
Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky Av. 4, 194064 St. Petersburg, Russia.
Publications dans "Protéine HMGB3" :
1 publication dans cette catégorie
Affiliations :
Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky Av. 4, 194064 St. Petersburg, Russia.
Publications dans "Protéine HMGB3" :
1 publication dans cette catégorie
Affiliations :
Institute of Cytology of the Russian Academy of Sciences, Tikhoretsky Av. 4, 194064 St. Petersburg, Russia.
Publications dans "Protéine HMGB3" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmacology, CSIR-Central Drug Research Institute, Lucknow 226031, India; Academy of Science and Innovation Research, New Delhi, India.
Publications dans "Protéine HMGB3" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmacology, CSIR-Central Drug Research Institute, Lucknow 226031, India; Academy of Science and Innovation Research, New Delhi, India.
Publications dans "Protéine HMGB3" :
Ovarian cancer, particularly epithelial ovarian cancer (EOC), is the leading cause of cancer-related mortality among women. Our previous study revealed that high HMGB3 levels are associated with poor ...
MTT, clonogenic, and EdU assays were used to assess cell proliferation. Transwell assays were performed to detect cell migration and invasion. Signaling pathways involved in HMGB3 function were identi...
HMGB3 knockdown inhibited ovarian cancer cell proliferation and metastasis, whereas HMGB3 overexpression facilitated these processes. RNA-seq showed that HMGB3 participates in regulating stem cell plu...
HMGB3 promotes ovarian cancer malignant phenotypes and stemness through the MAPK/ERK signaling pathway. Targeting HMGB3 is a promising strategy for ovarian cancer treatment that may improve the progno...
HMGB3 protein belongs to the group of HMGB proteins from the superfamily of nuclear proteins with high electrophoretic mobility. HMGB proteins play an active part in almost all cellular processes asso...
Circular RNAs (circRNAs) have been found to be associated with the development and progression of cancers including papillary thyroid carcinoma (PTC). Circ_LDLR has been reported to be highly expresse...
Previous evidences has highlighted the pivotal role of NOD-like receptor family pyrin domain-containing 3 (NLRP3)-mediated inflammasomes and pyroptosis activation in driving tumor malignancy and shapi...
Transcripts and protein levels of HMGB3, and cytokines associated with macrophage phenotypes and pyroptosis were assessed in glioma tissues and cell lines (U251, LN229, T98G, A172) using qRT-PCR and/o...
HMGB3 expression was elevated in glioma tissues, serum samples and tumor cell lines. Kaplan-Meier curves revealed a positive correlation between higher HMGB3 expression and poor overall survival and r...
These findings suggested that glioma cells secreted exosomal HMGB3 could facilitate macrophage M2 polarization, pyroptosis and inflammatory infiltration, indicating HMGB3 might be a poor prognosis fac...
Circular RNAs (circRNAs) are key factors in the regulation of cancer progression. However, the role of circRUNX1 in lung adenocarcinoma (LUAD) progression is unclear....
The expression levels of circRUNX1, microRNA (miR)-5195-3p, and high-mobility group protein B3 (HMGB3) were detected by quantitative real-time PCR. Cell proliferation, migration, invasion and apoptosi...
We found that circRUNX1 was upregulated in LUAD tumor tissues and cells. CircRUNX1 knockdown suppressed LUAD cell proliferation and metastasis, while promoted apoptosis. In terms of mechanism, we foun...
CircRUNX1 facilitated LUAD proliferation and metastasis by regulating the miR-5195-3p/HMGB3 axis, suggesting that it might be a possible therapeutic target for LUAD....
[This retracts the article DOI: 10.1155/2022/1954099.]....
Chronic inflammation and fibrosis are characteristics of silicosis, and the inflammatory mediators involved in silicosis have not been fully elucidated. Recently, macrophage-derived exosomes have been...
The induction of the inflammatory response and the recruitment of monocytes/macrophages were evaluated by immunofluorescence, flow cytometry and transwell assays. The expression of inflammatory cytoki...
HMGB3 expression was increased in exosomes derived from silica-exposed macrophages. Exosomal HMGB3 significantly upregulated the expression of inflammatory cytokines, activated the STAT3/MAPK (ERK1/2 ...
Exosomal HMGB3 is a proinflammatory modulator of silica-induced inflammation that promotes the inflammatory response and recruitment of monocytes/macrophages by regulating the activation of the STAT3/...
[This retracts the article DOI: 10.2147/CMAR.S276290.]....
Introduction The objective of the present study was to identify gene expression in peripheral blood by a real-time polymerase chain reaction (PCR) technique in patients who have lung carcinoma. Materi...
Recent studies have shown the pathogenesis of acute lung injury (ALI) involves circular RNA (circRNA). However, there are no data on the role of circSLCO3A1 in ALI and the underlying mechanism....
ALI-like cell injury was induced by stimulating human pulmonary alveolar epithelial cells (HPAEpiCs) using lipopolysaccharide (LPS). The expression of circSLCO3A1, miR-424-5p and high mobility group b...
CircSLCO3A1 and HMGB3 expression were significantly increased, while miR-424-5p was decreased in LPS-treated HPAEpiCs and the serum of septic ALI patients in comparison with controls. CircSLCO3A1 knoc...
CircSLCO3A1 absence assuaged LPS-induced HPAEpiC inflammation and apoptosis through the miR-424-5p/HMGB3 axis....
CircSLCO3A1 expression was upregulated in LPS-induced HPAEpiCs and sepsis-induced ALI patients.CircSLCO3A1 depletion protected against LPS-induced HPAEpiC disorders.CircSLCO3A1 bound to miR-424-5p in ...
The online version contains supplementary material available at 10.1007/s13273-023-00341-6....